Anavex Life Sciences (NASDAQ:AVXL) Issues Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Posted by Brian Himes on Jul 31st, 2026

Anavex Life Sciences (NASDAQ:AVXL – Get Free Report) issued its quarterly earnings data on Thursday. The biotechnology company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.01, FiscalAI reports.

Anavex Life Sciences Stock Up 8.4%

Shares of NASDAQ AVXL opened at $2.70 on Friday. The company’s fifty day moving average is $2.61 and its 200-day moving average is $3.45. The stock has a market cap of $250.21 million, a price-to-earnings ratio of -5.87 and a beta of 1.14. Anavex Life Sciences has a twelve month low of $2.26 and a twelve month high of $12.68.

Institutional Trading of Anavex Life Sciences

Several hedge funds have recently added to or reduced their stakes in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Anavex Life Sciences by 10.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 50,525 shares of the biotechnology company’s stock worth $434,000 after acquiring an additional 4,869 shares in the last quarter. Legal & General Group Plc lifted its position in Anavex Life Sciences by 19.0% in the 2nd quarter. Legal & General Group Plc now owns 86,972 shares of the biotechnology company’s stock valued at $802,000 after acquiring an additional 13,886 shares in the last quarter. Rhumbline Advisers boosted its stake in Anavex Life Sciences by 6.1% in the 2nd quarter. Rhumbline Advisers now owns 128,370 shares of the biotechnology company’s stock worth $1,184,000 after purchasing an additional 7,377 shares during the period. American Century Companies Inc. acquired a new position in shares of Anavex Life Sciences during the second quarter worth about $135,000. Finally, Prudential Financial Inc. bought a new position in shares of Anavex Life Sciences during the 2nd quarter worth approximately $95,000. Institutional investors and hedge funds own 31.55% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on AVXL shares. Weiss Ratings lowered shares of Anavex Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, June 11th. Rodman & Renshaw assumed coverage on Anavex Life Sciences in a research report on Monday, May 4th. They issued a “buy” rating and a $20.00 price target on the stock. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $21.33.

View Our Latest Stock Analysis on Anavex Life Sciences

Anavex Life Sciences Company Profile

(Get Free Report)

Anavex Life Sciences Corp is a clinical‐stage biopharmaceutical company focused on the development of novel therapeutics for central nervous system (CNS) disorders. The company applies a proprietary drug discovery platform that targets sigma‐1 and muscarinic receptors to modulate cellular stress pathways and support neuronal function. Headquartered in New York City, Anavex is dedicated to advancing treatments for neurodegenerative and neurodevelopmental diseases with high unmet medical need.

The company’s lead product candidate, blarcamesine (ANAVEX2‐73), is a small‐molecule activator of the sigma‐1 receptor currently being evaluated in clinical trials for Alzheimer’s disease and Parkinson’s disease dementia.